Tandem Diabetes Care (TNDM) Net Income Growth (3y) (2016 - 2026)

Tandem Diabetes Care (TNDM) Net Income Growth (3y) (2016 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Income Growth (3y) (Qtr)
1 Abbott Laboratories 182.32 Bn 175.02 Bn 6.27 Bn -6.51%
2 Stryker 128.75 Bn 125.88 Bn 3.81 Bn 7.96%
3 Medtronic 107.83 Bn 98.61 Bn 6.41 Bn 1.93%
4 Boston Scientific 67.61 Bn 66.15 Bn 3.61 Bn 62.29%
5 Edwards Lifesciences 48.13 Bn 44.45 Bn 1.29 Bn -
6 Dexcom 28.26 Bn 27.14 Bn 750.30 Mn 60.12%
7 GE HealthCare Technologies 27.78 Bn 25.50 Bn 1.98 Bn 2.38%
8 Smith & Nephew 26.99 Bn 26.41 Bn - -
9 Koninklijke Philips 23.92 Bn 20.80 Bn 2.07 Bn 280.49%
10 Tandem Diabetes Care 1.17 Bn 597.96 Mn 136.79 Mn 45.19%

Historic Data

Download Data
DateValue
Mar 31, 2026 45.19%
Dec 31, 2025 67.55%
Sep 30, 2025 24.38%
Jun 30, 2025 -51.59%
Mar 31, 2025 -106.93%
Dec 31, 2024 -58.76%
Sep 30, 2024 -82.12%
Jun 30, 2024 -113.29%
Mar 31, 2024 -103.10%
Dec 31, 2023 -55.51%
Sep 30, 2023 -51.88%
Jun 30, 2023 -6.96%
Mar 31, 2023 -102.74%
Dec 31, 2022 -99.93%
Sep 30, 2022 -156.49%
Jun 30, 2022 -115.11%
Mar 31, 2022 13.78%
Dec 31, 2021 42.91%
Sep 30, 2021 29.42%
Jun 30, 2021 30.79%